View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Project
1 June 2022

Mounjaro (tirzepatide) for the Treatment of Type 2 Diabetes

Mounjaro™ (tirzepatide) is a first-in-class GIP and GLP-1 receptor agonist for treating type 2 diabetes.
Mounjaro™ (tirzepatide) injection is a first-in-class GIP/GLP-1 receptor agonist indicated to treat type 2 diabetes in adults. Credit: Eli Lilly.
The drug is available in six doses, which can be subcutaneously administered by pre-filled single-dose auto-injector pen. Credit: Eli Lilly.
Type 2 diabetes is a chronic and progressive condition that results in unusual blood sugar levels. Credit: Jeanette Teare/Shutterstock.
Mounjaro is a dual-targeted therapy that combines the actions of the GIP and GLP-1 incretins into a single molecule. Credit: Eli Lilly.

Mounjaro™ (tirzepatide) is a dual-targeted, injectable therapy indicated for the management of type 2 diabetes (T2D) in adults as an adjunct to diet and exercise.

Developed by US-based pharmaceutical company Eli Lilly, Mounjaro is the first and only once-weekly glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist to improve blood glucose levels in adult type 2 diabetics.

Mounjaro was approved by the US Food and Drug Administration (FDA) for its indication in May 2022 after receiving priority review designation. The drug is also being reviewed by the regulatory authorities in Europe, Japan and several other countries for T2D treatment.

Mounjaro is available as a clear, colourless to slightly yellow solution in six doses. It comes in pre-filled single-dose auto-injector pens for subcutaneous administration.

Type 2 diabetes signs and symptoms

T2D is a chronic and progressive condition in which blood sugar regulation in the body is impaired, causing excessive sugar circulation in the bloodstream. High blood sugar levels can lead to circulatory, nervous, and immune system disorders.

T2D is the most common form of diabetes. It develops slowly and individuals with the condition can remain asymptomatic for years. Signs and symptoms of the disease can include increased thirst and hunger, frequent infection and urination, unintended weight loss, blurred vision, fatigue, slow-healing sores, and numbness or tingling sensations in the hands and feet.

Mounjaro’s mechanism of action

Mounjaro (tirzepatide) is a single molecule that selectively binds to and activates both the GIP and GLP-1 receptors to target GIP and GLP-1, the native incretin hormones.

The activation improves the secretion of both first and second-phase insulin and reduces glucagon levels, both in a glucose-dependent manner.

Clinical trials on Mounjaro

The FDA’s approval of Mounjaro was based on positive outcomes from a Phase III SURPASS programme that included five clinical trials, namely SURPASS-1, SURPASS-2, SURPASS-3, SURPASS-4 and SURPASS-5.

In SURPASS-1, Mounjaro was studied as a monotherapy. In SURPASS-2, SURPASS-3 and SURPASS-4, the drug was studied as an add-on to the common diabetes medications metformin, sulfonylureas, and/or sodium-glucose co-transporter 2 inhibitors (SGLT2 inhibitors). For SURPASS-5, Mounjaro was evaluated in combination with basal insulin with or without metformin.

Three doses of Mounjaro 5mg, 10mg and 15mg were used for evaluating the efficacy of the drug in the SURPASS programme. The doses were administered subcutaneously once weekly for comparison with placebo (SURPASS-1), semaglutide 1mg (SURPASS-2), insulin degludec (SURPASS-3), and/or insulin glargine (SURPASS-4).

The doses, in combination with basal insulin with or without metformin, were compared with placebo in T2D patients during the SURPASS-5 clinical study.

Patients with T2D who participated in the SURPASS programme achieved reductions of between 1.8% and 2.1% in their blood glucose levels on an average for Mounjaro 5mg dose, and between 1.7% and 2.4% for both 10mg and 15mg doses of Mounjaro.

Mounjaro delivered superior blood glucose level reductions against all comparators in the SURPASS programme. Use of the drug also led to significantly greater weight loss in patients than other comparators. The patients treated with 5mg dose lost 12lb of weight, while those treated with 15mg dose saw their weight reduce by 25lb.

The most common side effects reported in patients during the clinical trials were nausea, diarrhoea, decreased appetite, vomiting, constipation, indigestion, and abdominal pain.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena